[1] XIE T, GENG J, WANG Y, et al. FOXM1 evokes 5-fluorouracil resistance in colorectal cancer depending on ABCC10 [J]. Oncotarget, 2017, 8(5): 8574-8589.
[2] MAJIDINIA M, YOUSEFI B. Breast tumor stroma: A driving force in the development of resistance to therapies[J]. Chem Biol Drug Des, 2017, 89(3): 309-318.
[3] KOMOROWSKI M P, MCGRAY A R, KOLAKOWSKA A, et al. Reprogramming antitumor immunity against chemoresistant ovarian cancer by a CXCR4 antagonist-armed vi-ral oncotherapy[J]. Mol Ther Oncolytics, 2016, 3: 16034-16048.
[4] BRESNICK A R, WEBER D J, ZIMMER D B. S100 proteins in cancer[J]. Nat Rev Cancer, 2015, 15(2): 96-109.
[5] LI W L, ZHANG Y, LIU B G, et al. Correlation between the expression of S100A4 and the efficacy of TAC neoadjuvant chemotherapy in breast cancer[J]. Exp Ther Med, 2015, 10 (5): 1983-1989.
[6] BOYE K, JACOB H, FRIKSTAD K A, et al. Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy[J]. Cancer Med, 2016, 5(8): 1840-1849.
[7] KLOPPER J P, SHARMA V, BISSONNETTE R, et al. Combination PPARgamma and RXR Agonist Treatment in Melanoma cells: Functional Importance of S100A2[J]. PPAR Res, 2010, 2010: 729876.
[8] BRUHEIM S, XI Y, JU J, et al. Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide[J]. Clin Cancer Res, 2009, 15(23): 7161-7169.
[9] BACHET J B, MARECHAL R, DEMETTER P, et al. S100A2 is a predictive biomarker of adjuvant therapy benefit in pancreatic adenocarcinoma[J]. Eur J Cancer, 2013, 49 (12): 2643-2653.
[10] LEE K, YUN S T, YUN C O, et al. S100A2 promoter-driven conditionally replicative adenovirus targets non-small-cell lung carcinoma[J]. Gene Ther, 2012, 19(10): 967-977.
[11] LIU B, SUN W Y, ZHI C Y, et al. Role of S100A3 in human colorectal cancer and the anticancer effect of cantharidinate [J]. Exp Ther Med, 2013, 6(6): 1499-1503.
[12] LIANG D P, HUANG T Q, LI S J, et al. Knockdown of S100A4 chemosensitizes human laryngeal carcinoma cells in vitro through inhibition of Slug[J]. Eur Rev Med Pharmacol Sci, 2014, 18(22): 3484-3490.
[13] MA G, SUN Y, FU S. Evaluation of S100A4 mRNA in EUS-FNA specimens for the assessment of chemosensitivity to gemcitabine from patients with unresectable pancreatic cancer[J]. Int J Clin Exp Pathol, 2015, 8(10): 13284-13288.
[14] 李鹏, 刘江伟, 许永华, 等. siRNA干扰S100A4对人胰腺癌细胞增殖和凋亡及其对吉西他滨敏感性影响的研究[J]. 中华肿瘤防治杂志, 2012, 19(17): 1317-1320, 1325.
[15] YUAN T M, LIANG R Y, HSIAO N W, et al. The S100A4 D10V polymorphism is related to cell migration ability but not drug resistance in gastric cancer cells[J]. Oncol Rep, 2014, 32(6): 2307-2318.
[16] MENCIA N, SELGA E, RICO I, et al. Overexpression of S100A4 in human cancer cell lines resistant to methotrexate [J]. BMC Cancer, 2010, 10: 250-263.
[17] CAO C M, YANG F X, WANG P L, et al. Clinicopathologic significance of S100A4 expression in osteosarcoma[J]. Eur Rev Med Pharmacol Sci, 2014, 18(6): 833-839.
[18] REN X F, MU L P, JIANG Y S, et al. LY2109761 inhibits metastasis and enhances chemosensitivity in osteosarcoma MG-63 cells[J]. Eur Rev Med Pharmacol Sci, 2015, 19(7): 1182-1190.
[19] YANG M, ZENG P, KANG R, et al. S100A8 contributes to drug resistance by promoting autophagy in leukemia cells [J]. PLoS One, 2014, 9(5): e97242.
[20] ZHOU Z, LI Z, SUN Z, et al. S100A9 and ORM1 serve as predictors of therapeutic response and prognostic factors in advanced extranodal NK/T cell lymphoma patients treated with pegaspargase/gemcitabine[J]. Sci Rep, 2016, 6: 23695.
[21] JU W, YOO B C, KIM I J, et al. Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays[J]. Oncol Res, 2009, 18(2-3): 47-56.
[22] YANG W S, MOON H G, KIM H S, et al. Proteomic approach reveals FKBP4 and S100A9 as potential prediction markers of therapeutic response to neoadjuvant chemotherapy in patients with breast cancer[J]. J Proteome Res, 2012, 11(2): 1078-1088.
[23] ZHU H, PEI H P, ZENG S, et al. Profiling protein markers associated with the sensitivity to concurrent chemoradiotherapy in human cervical carcinoma[J]. J Proteome Res, 2009, 8(8): 3969-3976.
[24] JIN L, SHEN Q, DING S, et al. Immunohistochemical expression of Annexin A2 and S100A proteins in patients with bulky stage IB-IIA cervical cancer treated with neoadjuvant chemotherapy[J]. Gynecol Oncol, 2012, 126(1): 140-146.
[25] SUZUKI S, YAMAYOSHI Y, NISHIMUTA A, et al. Y S100A10 protein expression is associated with oxaliplatin sensitivity in human colorectal cancer cells[J]. Proteome Sci, 2011, 9: 76-88.
[26] SUZUKI S, TANIGAWARA Y. Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells[J]. Proteome Sci, 2014, 12: 26-36.
[27] ZAGRYAZHSKAYA A, SUROVA O, AKBAR N S, et al. Tudor staphylococcal nuclease drives chemoresistance of non-small cell lung carcinoma cells by regulating S100A11 [J]. Oncotarget, 2015, 6(14): 12156-12173.
[28] AZIMI A, PERNEMALM M, FROSTVIK STOLT M, et al. Proteomics analysis of melanoma metastases: association between S100A13 expression and chemotherapy resistance [J]. Br J Cancer, 2014, 110(10): 2489-2495.
[29] QIAN J, DING F, LUO A, et al. Overexpression of S100A14 in human serous ovarian carcinoma[J]. Oncol Lett, 2016, 11 (2): 1113-1119.
